BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPSC » Page 9

Dominance of Cellular Dynamics International (CDI) within iPSC Marketplace

By Leave a Comment

Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.

In theory, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.

In this article:

Cellular Dynamics International and iPSC Therapy

Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.

iPSC Market Competitors

In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:

  • Ocata Therapeutics
  • RIKEN
  • Kyoto University and CiRA
  • Fate Therapeutics
  • Megakaryon Corporation
  • Cynata Therapeutics

There are also a number of companies specializing in iPSC product development, including:

  • Allele Biotechnology
  • ALSTEM Bio
  • Applied Biological Materials (ABM)
  • Applied StemCell
  • Axol Bioscience
  • BrainXell
  • Cell Applications
  • Cellular Dynamics International (a Fujifilm Company)
  • EMD Millipore
  • Minerva Biotechnologies
  • Ncardia (formed through merger of Axiogenesis and Pluriomics)
  • Neucyte
  • Pluricell Biotech
  • REPROCELL
  • Sigma Aldrich (provides 350 iPSC lines through partnership with EBiSC)
  • STEMCELL Technologies
  • Stemgent (iPS Cell Business Unit owned by ReproCELL)
  • Takara Bio
  • Tempo Bioscience
  • Thermo Fisher Scientific
  • xCell Sciences
  • And others

Fujifilm Cellular Dynamics Inc.

Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.

[Read more…]

Could Cynata’s Cymerus™ Platform Be A Tool for Fighting the Pandemic?

By Leave a Comment

What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.

The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]

Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell

By 1 Comment

Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:

  1. Cell line generation for bio-production and bioassays
  2. Patient-relevant cell models for personalized medicine
  3. Physiologically predictive animal and cellular models of human disease

Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.

ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]

iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.

By 1 Comment

Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]

How 3D Printing with Stem Cells will Alter the Future of Medicine

By Leave a Comment

Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more. Among its exciting and varied applications, combining 3D printing technologies with stem cells is one of the most exciting.

For this reason, this article explores critical advances in 3D printing and how this technology is creating positive opportunities for stem cell companies and investors.

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0